Investment Thesis
Procept BioRobotics (NASDAQ: PRCT) is a leader in robotic-assisted surgical systems for benign prostatic hyperplasia (BPH) and other urological conditions. Its AquaBeam system uses waterjet ablation with real-time ultrasound guidance, offering superior outcomes compared to traditional TURP and laser therapies. The company is in the early innings of a multi-year growth cycle driven by installed base expansion, procedure volume growth, and international market penetration. With a market cap of ~$4B and revenue growing >50% YoY, PRCT is well-positioned to capture a significant share of the $5B+ BPH treatment market.
12-Month Catalysts
- Installed Base Acceleration: The company is ramping placements of its AquaBeam systems, with a target of 500+ systems by end of 2026 (from ~300 currently). Each new system drives recurring revenue from disposables and service contracts.
- Procedure Volume Growth: Same-store procedure growth is expected to remain above 30% as surgeons become more proficient and patient awareness increases. The company is also expanding into new indications like prostate cancer ablation.
- Margin Expansion: As the installed base scales, gross margins are improving (targeting 70%+ in the next 12-18 months) and operating leverage is driving a path to profitability. The company expects to achieve adjusted EBITDA breakeven by Q4 2026.
- International Expansion: Recent FDA clearance for the AquaBeam system in Japan and CE mark renewal in Europe open up large addressable markets. Initial placements in Japan are expected in H2 2026.
Key Risks
- Competition: Intuitive Surgical’s da Vinci system and other robotic platforms (e.g., from J&J, Medtronic) could enter the BPH space, though AquaBeam’s unique waterjet technology provides a moat.
- Reimbursement Headwinds: Any changes in Medicare or private payer reimbursement for Aquablation could impact procedure volumes and pricing.
Valuation Summary
PRCT trades at ~8x forward sales, which is a premium to the medtech peer group average of ~5x. However, given its >50% revenue growth and path to profitability, the PEG ratio is below 1.5x, indicating reasonable valuation for the growth profile. As margins expand and the company approaches breakeven, a multiple re-rating is likely.
Balance Sheet Summary
Procept has a strong balance sheet with $250M in cash and no debt as of Q1 2026. The company is well-capitalized to fund its growth initiatives without near-term dilution risk.
Disclaimer: This is not financial advice. Investing involves risk, including potential loss of principal. Please conduct your own due diligence.